International collaborative proficiency study of Human Papillomavirus type 16 serology
- 5 January 2012
- Vol. 30 (2), 294-299
- https://doi.org/10.1016/j.vaccine.2011.10.096
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 yearsHuman Vaccines, 2009
- WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24–25 January 2008, Geneva, SwitzerlandVaccine, 2009
- Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccineHuman Vaccines, 2008
- Seroepidemiology as basis for design of a human papillomavirus vaccination programVaccine, 2008
- Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomavirusesInternational Journal of Cancer, 2005
- A population-based study of cervical carcinoma and HPV infection in LatviaGynecologic Oncology, 2004
- Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Virology, 2004
- Evaluation of cost–precision rations of different strategies for ELISA measurement of serum antibody levelsJournal of Immunological Methods, 2002
- Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle VaccineJNCI Journal of the National Cancer Institute, 2001